Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.
about
Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigenPathogenesis of human immunodeficiency virus infectionMatrix-M Adjuvated Seasonal Virosomal Influenza Vaccine Induces Partial Protection in Mice and Ferrets against Avian H5 and H7 ChallengeRecent advances of vaccine adjuvants for infectious diseasesAdjuvants and antibody production: dispelling the myths associated with Freund's complete and other adjuvantsSaponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formationControl of influenza virus infection by immunity to conserved viral features.Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strainDevelopment of a vaccine against pandemic influenza viruses: current status and perspectives.Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccinesAdministration of superantigens protects mice from lethal Listeria monocytogenes infection by enhancing cytotoxic T cells.Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic indexComparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance.Delivery of foreign antigens by engineered outer membrane vesicle vaccines.Characterization of an experimental vaccine for bovine respiratory syncytial virus.ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.Accessibility of gonococcal and meningococcal surface antigens: immunogold labeling for quantitative electron microscopy.Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in miceSurvey of human-use adjuvants.Risks connected with the use of conventional and genetically engineered vaccines.Immunity against Yersinia enterocolitica by vaccination with Yersinia HSP60 immunostimulating complexes or Yersinia HSP60 plus interleukin-12Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A.Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720).Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvantStructure of immune stimulating complex matrices and immune stimulating complexes in suspension determined by small-angle x-ray scattering.Lipid based particulate formulations for the delivery of antigen.ISCOM-based vaccines: the second decade.Expression of recombinant proteins on the surface of the coagulase-negative bacterium Staphylococcus xylosus.Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future NeedsMeasles virus transmembrane fusion protein synthesized de novo or presented in immunostimulating complexes is endogenously processed for HLA class I- and class II-restricted cytotoxic T cell recognition.Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.Characterization and specificity of antibodies to protein I of Neisseria gonorrhoeae produced by injection with various protein I-adjuvant preparations.Cross-linked protein crystals for vaccine deliveryFunctionalization of immunostimulating complexes (ISCOMs) with lipid vinyl sulfones and their application in immunological techniques and therapy.Immunostimulatory colloidal delivery systems for cancer vaccines.Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.Particulate delivery systems for vaccines: what can we expect?Human HLA class I- and HLA class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein
P2860
Q21134130-33EBB428-677E-433C-BB63-0B6612412357Q24634681-D35F8B66-ECEF-4479-8128-5D869157459CQ27300233-4F4773EA-3EF5-47AB-8CBA-4EDBE59F5367Q28083679-9CB20424-A59C-4299-8228-F007FBF2BF42Q28256294-72A894C1-800F-41E9-99D6-023C26EB6AACQ28393754-3E14AD95-F8FB-4615-BD87-B946DE4114ECQ30343902-72341093-5652-4D63-94DC-06CA249F4105Q30351385-6DD54B6E-79B0-40B4-8EBC-0D823287D213Q30373784-3C20EE7A-310F-42B3-A05D-2AAA8FCE7573Q30403760-C0344E3B-ECE5-414D-8A5E-555BC6C3167EQ30408295-804F31CB-2414-46B5-A072-7987591C1E0AQ33551984-EF625660-C9B8-4C23-A818-BF3BA12E9524Q33644858-49424B96-C37D-4375-BB06-FFA46EFF2521Q33645053-FE7B0E4C-2337-4A2C-BEEC-1FEEFBFB3BBFQ33733590-EAF7FF28-802B-4602-AB7D-6C35F3346721Q33899379-4F771733-DFFB-4AC2-B0CD-91A0FF10AF7BQ34848159-56E1D4D5-C81A-4E65-8CBA-A42AEB9151A3Q35091034-DCD445E5-4E70-442E-8050-B35767500752Q35091726-694B18FE-2E91-46D6-B385-2DE2C9B33D06Q35192171-B2A74180-2AC7-41C3-8680-D920C40024ADQ35433650-FDEB6F12-7121-4612-9708-9270816257D8Q35509504-AC84D7B3-F82E-4149-9A15-D86F72D5D090Q35613832-F12C059E-B71E-4ACF-8DC6-9880BA4DFEECQ35833323-B7C3E189-CAFF-49F6-A340-58E83651487AQ35887397-6298E061-9750-47CB-8536-14A0C52265C7Q35962580-3234F772-F90D-4C53-A698-8D8BED49F9B8Q36062119-CFB3F423-23AF-425E-890F-2A61FFE82FD4Q36062124-2242006A-AACC-4435-9FA4-3B22E84556EFQ36113480-5E80088B-E67A-4892-8AA3-A9348602B187Q36191001-F8CECA84-81BA-44C6-BBEE-6820B5DD7C04Q36231571-8DFCF163-54B1-4B54-8E64-1E7BDCD97DA5Q36354085-90F27117-E595-4CAE-98BB-66709C1B3C6DQ36355632-CCE8CB71-8E5F-47FE-B5F8-D968D393DF13Q36420836-923EBE26-3FF6-4DD4-9D11-16DEFE63BDB6Q36456012-CC835282-A0B7-44C1-9513-D3E611D924BDQ36460849-E9DB8B17-E2B7-484E-B53D-D2414D3D3B2DQ36466129-0F358973-D645-466C-92F9-B39A50941D36Q36471827-B299D42A-CDF1-40D9-8EC1-5E8D9FD4842DQ36492598-C6728C4C-3C18-473F-86EA-0BE8B4A8AC0CQ36686798-F5DD56BC-C324-476B-974F-A4C5ABA7AF5E
P2860
Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Iscom, a novel structure for a ...... oteins from enveloped viruses.
@en
Iscom, a novel structure for a ...... oteins from enveloped viruses.
@nl
type
label
Iscom, a novel structure for a ...... oteins from enveloped viruses.
@en
Iscom, a novel structure for a ...... oteins from enveloped viruses.
@nl
prefLabel
Iscom, a novel structure for a ...... oteins from enveloped viruses.
@en
Iscom, a novel structure for a ...... oteins from enveloped viruses.
@nl
P2093
P356
P1433
P1476
Iscom, a novel structure for a ...... oteins from enveloped viruses.
@en
P2093
Dalsgaard K
Osterhaus A
Sundquist B
P2860
P2888
P304
P356
10.1038/308457A0
P407
P577
1984-03-01T00:00:00Z
P6179
1019446715